NO20022201L - Lösninger inneholdende Epinastin - Google Patents

Lösninger inneholdende Epinastin

Info

Publication number
NO20022201L
NO20022201L NO20022201A NO20022201A NO20022201L NO 20022201 L NO20022201 L NO 20022201L NO 20022201 A NO20022201 A NO 20022201A NO 20022201 A NO20022201 A NO 20022201A NO 20022201 L NO20022201 L NO 20022201L
Authority
NO
Norway
Prior art keywords
solutions containing
containing epinastine
optionally
epinastine
racemate
Prior art date
Application number
NO20022201A
Other languages
English (en)
Other versions
NO329417B1 (no
NO20022201D0 (no
Inventor
Volker Trach
Gerold Duschler
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7928843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20022201(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20022201L publication Critical patent/NO20022201L/no
Publication of NO20022201D0 publication Critical patent/NO20022201D0/no
Publication of NO329417B1 publication Critical patent/NO329417B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01L—CYCLICALLY OPERATING VALVES FOR MACHINES OR ENGINES
    • F01L9/00—Valve-gear or valve arrangements actuated non-mechanically
    • F01L9/20—Valve-gear or valve arrangements actuated non-mechanically by electric means
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T137/00—Fluid handling
    • Y10T137/0318—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Detergent Compositions (AREA)

Abstract

Oppfinnelsen angår topisk administrerte vandige løsninger inneholdende epinastin, eventuelt i form av dens racemat eller dens enantiomerer og eventuelt i form av de farmakologisk akseptable syreaddisjonssalter derav.
NO20022201A 1999-11-12 2002-05-08 Anvendelse av losninger inneholdende epinastin for fremstilling av medikamenter for behandling av sykdom NO329417B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19954516A DE19954516A1 (de) 1999-11-12 1999-11-12 Epinastin-haltige Lösungen
PCT/EP2000/010122 WO2001035962A1 (de) 1999-11-12 2000-10-14 Epinastin-haltige lösungen

Publications (3)

Publication Number Publication Date
NO20022201L true NO20022201L (no) 2002-05-08
NO20022201D0 NO20022201D0 (no) 2002-05-08
NO329417B1 NO329417B1 (no) 2010-10-18

Family

ID=7928843

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022201A NO329417B1 (no) 1999-11-12 2002-05-08 Anvendelse av losninger inneholdende epinastin for fremstilling av medikamenter for behandling av sykdom

Country Status (40)

Country Link
US (6) US20030050303A1 (no)
EP (1) EP1231920B1 (no)
JP (1) JP2003514021A (no)
KR (1) KR100758842B1 (no)
CN (1) CN1292752C (no)
AR (1) AR026424A1 (no)
AT (1) ATE353218T1 (no)
AU (2) AU784017B2 (no)
BG (1) BG65775B1 (no)
BR (1) BR0015477A (no)
CA (1) CA2391076C (no)
CO (1) CO5251448A1 (no)
CY (1) CY1106375T1 (no)
CZ (1) CZ302483B6 (no)
DE (2) DE19954516A1 (no)
DK (1) DK1231920T3 (no)
EA (1) EA006937B1 (no)
EE (1) EE05395B1 (no)
ES (1) ES2281359T3 (no)
HK (1) HK1052303B (no)
HR (1) HRP20020404B1 (no)
HU (1) HU229502B1 (no)
IL (2) IL149501A0 (no)
ME (1) MEP36708A (no)
MX (1) MXPA02004556A (no)
MY (1) MY130441A (no)
NO (1) NO329417B1 (no)
NZ (1) NZ519425A (no)
PE (1) PE20010826A1 (no)
PL (1) PL198879B1 (no)
PT (1) PT1231920E (no)
RS (1) RS50173B (no)
SA (1) SA01210658B1 (no)
SI (1) SI1231920T1 (no)
SK (1) SK287343B6 (no)
TR (1) TR200201270T2 (no)
TW (1) TWI225401B (no)
UA (1) UA74563C2 (no)
WO (1) WO2001035962A1 (no)
ZA (1) ZA200203683B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
AU2003250073A1 (en) * 2002-08-02 2004-02-25 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine
EP1468696A1 (en) * 2003-04-17 2004-10-20 Boehringer Ingelheim International GmbH Combinations of epinastine and antiphlogisitcs as new pharmaceutical compositions for the treatment of skin diseases
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
WO2007007851A1 (en) * 2005-07-08 2007-01-18 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising epinastine
US7378082B1 (en) 2007-11-05 2008-05-27 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects
WO2008098122A2 (en) * 2007-02-08 2008-08-14 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects
US20080194544A1 (en) * 2007-02-08 2008-08-14 Ramesh Krishnamoorthy Aqueous formulations of epinastine for treating allergic rhinitis
WO2011019940A2 (en) * 2009-08-12 2011-02-17 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method for use
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
PL2934510T3 (pl) * 2012-12-19 2021-07-05 Novartis Ag Formulacje inhibitora lfa-1
CN104491876A (zh) * 2014-12-23 2015-04-08 中国药科大学 含玻璃酸钠的依匹斯汀滴眼液及其制备方法
ITUB20153950A1 (it) * 2015-09-28 2017-03-28 Tred Srl Dispositivo nasale in grado di attivare il riflesso rino-palatale per l'igienizzazione rinofaringea
JP6134853B1 (ja) * 2016-10-28 2017-05-24 参天製薬株式会社 エピナスチン含有点眼液
JP6635974B2 (ja) * 2017-04-24 2020-01-29 参天製薬株式会社 エピナスチン含有点眼液
KR20230136703A (ko) * 2017-05-01 2023-09-26 산텐 세이야꾸 가부시키가이샤 점안제
JP2019108320A (ja) * 2018-10-31 2019-07-04 参天製薬株式会社 ソフトコンタクトレンズの変質を抑制する眼科用組成物
JP6736752B2 (ja) * 2019-12-17 2020-08-05 参天製薬株式会社 エピナスチン含有点眼液
JP7118579B1 (ja) 2020-04-16 2022-08-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性組成物
JP6963651B2 (ja) * 2020-04-16 2021-11-10 参天製薬株式会社 エピナスチン又はその塩を含有する水性組成物
JP2020169213A (ja) * 2020-07-15 2020-10-15 参天製薬株式会社 エピナスチン含有点眼液
CN115448927A (zh) * 2022-10-20 2022-12-09 重庆瑞泊莱医药科技有限公司 一种氢溴酸依匹斯汀晶型ii及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US151541A (en) * 1874-06-02 Improvement in hay-loaders
US228359A (en) * 1880-06-01 jones
US8632A (en) * 1852-01-06 George hess
US203021A (en) * 1878-04-30 Improvement in side-bar wagons
US215396A (en) * 1879-05-13 Improvement in loom-temples
US181478A (en) * 1876-08-22 Improvement in water-wheels
US104017A (en) * 1870-06-07 Improvement in embroidering attachment for sewing-machines
DE3008944A1 (de) * 1980-03-08 1981-09-24 C.H. Boehringer Sohn, 6507 Ingelheim Dibenzimidazoazepine, ihre herstellung und verwendung
DE4102148A1 (de) * 1991-01-25 1992-07-30 Boehringer Ingelheim Kg Verfahren zur herstellung von 3-amino-9,13b-dihydro-1h-dibenz-(c,f)imidazol(1,5-a)azepin-hydrochlorid
US5668133A (en) * 1992-12-09 1997-09-16 Alcon Laboratories, Inc. Ophthalmic compositions comprising emedastine and methods for their use
RU2223750C2 (ru) * 1995-06-27 2004-02-20 Берингер Ингельхайм КГ Лекарственная композиция в виде раствора, предназначенная для получения способного к ингаляции аэрозоля
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
CA2264172A1 (en) * 1996-08-30 1998-03-05 Kyoto Pharmaceutical Industries, Ltd. Remedies for allergic dermatitis
US20030215396A1 (en) * 1999-09-15 2003-11-20 Boehringer Ingelheim Pharma Kg Method for the production of propellant gas-free aerosols from aqueous medicament preparations
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
MXPA02005007A (es) * 1999-11-18 2004-08-12 Alcon Inc Uso de un antagonista h1 y un esteroide inocuo para tratar condiciones oculares.
DE19958460A1 (de) * 1999-12-03 2001-06-07 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Epinastine-Hydrochlorid in der hochschmelzenden Kristallmodifikation
FR2803520B1 (fr) * 2000-01-12 2002-09-20 Ceva Sante Animale Procede pour augmenter la production d'oeufs et consolider la coquille des oeufs chez les volailles
US20020094345A1 (en) * 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
DE10119718A1 (de) * 2001-04-21 2002-10-31 Boehringer Ingelheim Pharma Verfahren zur kontinuierlichen Herstellung inhalierfähiger Arzneistoffe, Vorrichtung zur Durchführung des Verfahrens und nach diesem Verfahren hergestellter Arzneistoff
US7420602B2 (en) * 2001-05-29 2008-09-02 Samsung Semiconductor Israel R&D Center (Sirc) Cmos imager for cellular applications and methods of using such
US20030104017A1 (en) * 2001-10-26 2003-06-05 Boehringer Ingelheim International Gmbh Epinastine formulation for oral administration
EP1350512A1 (en) * 2002-04-03 2003-10-08 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
US6863848B2 (en) * 2002-08-30 2005-03-08 Signet Armorlite, Inc. Methods for preparing composite photochromic ophthalmic lenses
JP2007145316A (ja) * 2005-10-27 2007-06-14 Nissan Motor Co Ltd 遮光装置とサンバイザーとサンルーフユニット

Also Published As

Publication number Publication date
CN1390129A (zh) 2003-01-08
CZ302483B6 (cs) 2011-06-08
EA006937B1 (ru) 2006-06-30
IL149501A0 (en) 2002-11-10
US20070197503A1 (en) 2007-08-23
NO329417B1 (no) 2010-10-18
US20030050303A1 (en) 2003-03-13
US20080009476A1 (en) 2008-01-10
NZ519425A (en) 2004-04-30
ATE353218T1 (de) 2007-02-15
TR200201270T2 (tr) 2002-12-23
HUP0203773A3 (en) 2005-01-28
HRP20020404B1 (en) 2007-08-31
KR100758842B1 (ko) 2007-09-19
CA2391076C (en) 2008-06-17
BG65775B1 (bg) 2009-11-30
ZA200203683B (en) 2003-09-03
PL364028A1 (en) 2004-11-29
MEP36708A (en) 2011-02-10
SA01210658B1 (ar) 2006-11-05
DE19954516A1 (de) 2001-05-17
HK1052303B (zh) 2007-04-13
AU784017B2 (en) 2006-01-12
WO2001035962A1 (de) 2001-05-25
AU1138101A (en) 2001-05-30
IL149501A (en) 2012-04-30
MXPA02004556A (es) 2004-09-10
YU33602A (sh) 2005-03-15
JP2003514021A (ja) 2003-04-15
US20070185082A1 (en) 2007-08-09
CA2391076A1 (en) 2001-05-25
HRP20020404A2 (en) 2004-08-31
HUP0203773A2 (hu) 2003-03-28
EE05395B1 (et) 2011-04-15
SK287343B6 (sk) 2010-07-07
EA200200492A1 (ru) 2002-10-31
SI1231920T1 (sl) 2007-06-30
PL198879B1 (pl) 2008-07-31
US20050288274A1 (en) 2005-12-29
KR20020050273A (ko) 2002-06-26
ES2281359T3 (es) 2007-10-01
US20090239842A1 (en) 2009-09-24
CO5251448A1 (es) 2003-02-28
EE200200246A (et) 2003-06-16
DK1231920T3 (da) 2007-04-10
UA74563C2 (uk) 2006-01-16
CZ20021956A3 (cs) 2002-08-14
AU2006201541A1 (en) 2006-05-11
US7429602B2 (en) 2008-09-30
BR0015477A (pt) 2002-06-25
EP1231920A1 (de) 2002-08-21
PT1231920E (pt) 2007-03-30
EP1231920B1 (de) 2007-02-07
DE50014041D1 (de) 2007-03-22
PE20010826A1 (es) 2001-08-20
BG106681A (en) 2002-12-29
MY130441A (en) 2007-06-29
RS50173B (sr) 2009-05-06
SK8302002A3 (en) 2002-09-10
HU229502B1 (en) 2014-01-28
NO20022201D0 (no) 2002-05-08
TWI225401B (en) 2004-12-21
HK1052303A1 (en) 2003-09-11
AR026424A1 (es) 2003-02-12
CN1292752C (zh) 2007-01-03
CY1106375T1 (el) 2011-10-12

Similar Documents

Publication Publication Date Title
NO20022201L (no) Lösninger inneholdende Epinastin
YU44404A (sh) Postupak za identifikovanje ciljnih enzima tumora
BR9810450A (pt) Derivados de ácido barbitúrico com atividade antimetastática e antitumor
ATE495187T1 (de) Dalda-analoge und ihre verwendung
TR199900486T2 (xx) Aziniloksi ve fenoksi-diaril-karbonasit t�revleri.
DE60111362D1 (de) Stabilisierte ascorbinsäure-lösungen
PL357132A1 (en) Stable, nasally, orally or sublingually applicable pharmaceutical preparation
IS6284A (is) Meðhöndlun á mígreni með því að gefa alfa-lípósýru eða afleiður hennar
ATE295165T1 (de) Mittel zur adjuvanten therapie von demenzen enthaltend alpha-liponsäure
EA200101150A1 (ru) Раствор прукалоприда для перорального применения
FI980902A0 (fi) Levosimendaanin stabiileja koostumuksia
DE60003074D1 (de) Fusidinsäure-derivate
TR200000890T2 (tr) Topik ilacın üretilmesi için -amino levülozik asidin kullanılması
DK1173065T3 (da) Anvendelse af cellulosemikrofibriller i fermenterede mælkepræparater
UA31788A (uk) Спосіб лікування мікозів з вираженими проявами гіперкератозу

Legal Events

Date Code Title Description
MK1K Patent expired